Table 4. Incidence (any grade) of adverse events of special interest.
| Incidence, % |
Patients with liver metastases |
Patients without liver metastases |
||
|---|---|---|---|---|
| AA+P (n=88) | P (n=28) | AA+P (n=703) | P (n=366) | |
| Fluid retention/edema | 36.4 | 28.6 | 32.6 | 23.5 |
| LFT abnormalitiesa | 19.3 | 14.3 | 10.2 | 8.5 |
| Cardiac disorders | 15.9 | 7.1 | 15.9 | 12.0 |
| Hypokalemia | 15.9 | 7.1 | 18.3 | 9.3 |
| Hypertension | 3.4 | 0 | 12.1 | 8.7 |
Abbreviations: AA, abiraterone acetate; LFT, liver function test; P, prednisone.
a
Higher incidence of LFT abnormalities is to be expected in patients with liver involvement.